Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
In this supplement, the authors comprehensively review molecular and clinical evidence underlying the evolution of poly (ADP-ribose) polymerase (PARP) inhibitors in a journey spanning 50 years, which culminates in the recent licensing approval of the first oral PARP inhibitor, olaparib (Lynparzat™), for BRCA-mutated high-grade serous ovarian cancer.